Вы находитесь на странице: 1из 8

Ulcerative Colitis - Pipeline Review, H2 2015 Now

Available at iData Insights


Ulcerative Colitis - Pipeline Review, H2 2015 Summary Global Markets Direct s, Ulcerative Colitis Pipeline Review, H2 2015, provides an overview of the Ulcerative Colitis s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Ulcerative Colitis,
complete with comparative analysis at various stages, therapeutics assessment by drug target,
mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates,
and featured news and press releases. It also reviews key players involved in the therapeutic
development for Ulcerative Colitis and special features on late-stage and discontinued projects. Global
Markets Directs sfr products Reasons to buy - Provides strategically significant competitor information,
analysis, and insights to formulate effective R&D development strategies - Identify emerging players
with potentially strong product portfolio and create effective counter-strategies to gain competitive
advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Ulcerative
Colitis - Plan mergers and acquisitions effectively by identifying key players of the most promising
pipeline - Devise corrective measures for pipeline projects by understanding Ulcerative Colitis pipeline
depth and focus of fh2-2015
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Ulcerative Colitis Overview 12
Therapeutics Development 13
Pipeline Products for Ulcerative Colitis - Overview 13
Pipeline Products for Ulcerative Colitis - Comparative Analysis 14
Ulcerative Colitis - Therapeutics under Development by Companies 15
Ulcerative Colitis - Therapeutics under Investigation by Universities/Institutes 22

Ulcerative Colitis - Pipeline Products Glance 23


Late Stage Products 23
Clinical Stage Products 24
Early Stage Products 25
Unknown Stage Products 26
Ulcerative Colitis - Products under Development by Companies 27
Ulcerative Colitis - Products under Investigation by Universities/Institutes 32
Ulcerative Colitis - Companies Involved in Therapeutics Development 33
4D Pharma Plc 33
Advinus Therapeutics Ltd. 34
Ajinomoto Pharmaceuticals Co., Ltd. 35
Altheus Therapeutics, Inc. 36
Am-Pharma B.V. 37
Amgen Inc. 38
Arena Pharmaceuticals, Inc. 39
Astellas Pharma Inc. 40
Atlantic Healthcare Plc 41
Avaxia Biologics, Inc. 42
BioAtla, LLC 43
BioLineRx, Ltd. 44
Bionovis SA 45
Celgene Corporation 46
Cellceutix Corporation 47
Celltrion, Inc. 48
2

ChemoCentryx, Inc. 49
ChironWells GmbH 50
Chong Kun Dang Pharmaceutical Corp. 51
Cosmo Pharmaceuticals S.p.A 52
Dr. Falk Pharma GmbH 53
Effimune SAS 54
Eli Lilly and Company 55
Emergent BioSolutions Inc. 56
Enceladus Pharmaceuticals BV 57
enGene, Inc 58
Enterome Bioscience SA 59
Epirus Biopharmaceuticals, Inc. 60
Flexion Therapeutics, Inc. 61
Galapagos NV 62
Genentech, Inc. 63
Genor BioPharma Co., Ltd. 64
Gilead Sciences, Inc. 65
GW Pharmaceuticals Plc 66
Hetero Drugs Limited 67
iCo Therapeutics Inc. 68
Idera Pharmaceuticals, Inc. 69
InDex Pharmaceuticals AB 70
Innovate Biopharmaceuticals, Inc. 71
3

INOXIA Lifesciences GmbH 72


Intas Pharmaceuticals Ltd. 73
Invion Limited 74
Johnson & Johnson 75
Kaken Pharmaceutical Co., Ltd. 76
Kymab Limited 77
LIPID THERAPEUTICS GmbH 78
LTT Bio-Pharma Co., Ltd. 79
Mabion SA 80
Mabtech Limited 81
Medestea Research & Production S.p.A. 82
Momenta Pharmaceuticals, Inc. 83
Morphotek, Inc. 84
Mycenax Biotech Inc. 85
Oncobiologics, Inc. 86
Pfizer Inc. 87
Pluristem Therapeutics Inc. 88
ProtAb Ltd 89
Protagonist Therapeutics Inc. 90
Qu Biologics Inc. 91
Rebiotix Inc. 92
Receptos, Inc. 93
Sandoz International GmbH 94
Seres Therapeutics, Inc. 95
4

Sigmoid Pharma Limited 96


Stelic Institute & Co. 97
sterna biologicals Gmbh & Co KG 98
Synergy Pharmaceuticals, Inc. 99
Takeda Pharmaceutical Company Limited 100
Therapeutic Proteins International, LLC 101
Therapix Biosciences Ltd 102
Theravance Biopharma, Inc. 103
Tillotts Pharma AG 104
Trino Therapeutics Limited 105
Ventria Bioscience 106
Zyngenia, Inc. 107
Ulcerative Colitis - Therapeutics Assessment 108
Assessment by Monotherapy Products 108
Assessment by Combination Products 109
Assessment by Target 110
Assessment by Mechanism of Action 115
Assessment by Route of Administration 119
Assessment by Molecule Type 121
Drug Profiles 123
(mesalamine + N-acetylcysteine) - Drug Profile 123
abrilumab - Drug Profile 125
ABS-11 - Drug Profile 126
5

adalimumab biosimilar - Drug Profile 127


adalimumab biosimilar - Drug Profile 128
adalimumab biosimilar - Drug Profile 129
adalimumab biosimilar - Drug Profile 130
adalimumab biosimilar - Drug Profile 131
adalimumab biosimilar - Drug Profile 132
adalimumab biosimilar - Drug Profile 133
adalimumab biosimilar - Drug Profile 134
adalimumab biosimilar - Drug Profile 135
adalimumab biosimilar - Drug Profile 136
adalimumab biosimilar - Drug Profile 137
adalimumab biosimilar - Drug Profile 138
adalimumab biosimilar - Drug Profile 139
AJM-300 - Drug Profile 140
AKP-11 - Drug Profile 142
alicaforsen sodium - Drug Profile 144
Anatabine - Drug Profile 145
Antisense RNAi Oligonucleotide to Inhibit microRNA-214 for Ulcerative Colitis and Colon Cancer - Drug
Profile 147
APD-334 - Drug Profile 148
apremilast - Drug Profile 149
ASP-3291 - Drug Profile 152
AVX-470 - Drug Profile 153
AW/EPO-002 - Drug Profile 155
6

AW/EPO-003 - Drug Profile 156


AW/EPOPD-01 - Drug Profile 157
AW/EPOPD-02 - Drug Profile 158
AW/EPOPD-06 - Drug Profile 159
bertilimumab - Drug Profile 160
BL-7040 - Drug Profile 162
brilacidin tetrahydrochloride - Drug Profile 164
budesonide - Drug Profile 166
CCX-507 - Drug Profile 169
CKD-506 - Drug Profile 170
cyclosporine CR - Drug Profile 171
D-9030 - Drug Profile 172
DIMS-0150 - Drug Profile 173
dolcanatide - Drug Profile 176
Drug to Inhibit Phospholipase A2 for Crohn's Disease and Ulcerative Colitis - Drug Profile 177
Drugs for Ulcerative Colitis - Drug Profile 178
EB-120 - Drug Profile 179
EFFI-7H - Drug Profile 180
EG-10 - Drug Profile 181
EG-12 - Drug Profile 182
enalaprilat - Drug Profile 183
ES-210 - Drug Profile 184
Read More http://www.idatainsights.com/reports-landing-page.php?id=179089/ulcerative-colitispipeline-review-h2-2015
7

About Us:
iData Insights which operates under Precision Research and Consulting Private Limited is a leading
market research information aggregator and marketing research consulting firm. We conduct both
primary and secondary research. Our work does not end with research it is also involved in distributing
reports for different companies . We provide actionable recommendations and provide our expertise for
business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and
discovery, and then be their guide in the implementation of changes that will make a difference to their
bottom line.
ContactUs:
iData Insights
Tel: 1-866-237-2965
Web: http://www.idatainsights.com
Email: info@idatainsights.com
About iData Insights
We work around the clock until our clients are completely satisfied with their promised results. It is our
mission to provide timely services coupled with acute client care to create a long-lasting relationship
with you. We deliver on our promise to provide results that are essential to the success of your
company. We believe that by doing so, we will earn the trust of our clients for future project.